[go: up one dir, main page]

CO2023000130A2 - Composición y método para el tratamiento del dolor crónico - Google Patents

Composición y método para el tratamiento del dolor crónico

Info

Publication number
CO2023000130A2
CO2023000130A2 CONC2023/0000130A CO2023000130A CO2023000130A2 CO 2023000130 A2 CO2023000130 A2 CO 2023000130A2 CO 2023000130 A CO2023000130 A CO 2023000130A CO 2023000130 A2 CO2023000130 A2 CO 2023000130A2
Authority
CO
Colombia
Prior art keywords
chronic pain
treatment
composition
relates
cannabigerol
Prior art date
Application number
CONC2023/0000130A
Other languages
English (en)
Inventor
Richard Hopkins
Meghan Gail Thomas
Oludare Odumosu
Original Assignee
Zelira Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901947A external-priority patent/AU2020901947A0/en
Application filed by Zelira Therapeutics Operations Pty Ltd filed Critical Zelira Therapeutics Operations Pty Ltd
Publication of CO2023000130A2 publication Critical patent/CO2023000130A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas que comprenden Δ9-tetrahidrocannabinol (THC), cannabidiol (CBD) y cannabigerol (CBG) y un componente terpeno, y su uso en el tratamiento del dolor crónico. La invención también se refiere a métodos para tratar el dolor crónico, especialmente el dolor crónico en atletas.
CONC2023/0000130A 2020-06-12 2023-01-06 Composición y método para el tratamiento del dolor crónico CO2023000130A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2020901947A AU2020901947A0 (en) 2020-06-12 Composition and method for treating chronic pain
PCT/AU2021/050602 WO2021248207A1 (en) 2020-06-12 2021-06-11 Composition and method for treating chronic pain

Publications (1)

Publication Number Publication Date
CO2023000130A2 true CO2023000130A2 (es) 2023-05-19

Family

ID=78523907

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0000130A CO2023000130A2 (es) 2020-06-12 2023-01-06 Composición y método para el tratamiento del dolor crónico

Country Status (14)

Country Link
US (1) US20230218566A1 (es)
EP (1) EP4164628A4 (es)
JP (1) JP2023529476A (es)
KR (1) KR20230069080A (es)
CN (1) CN115843248A (es)
AU (1) AU2021215262B2 (es)
BR (1) BR112022025302A2 (es)
CA (1) CA3186718A1 (es)
CL (1) CL2022003507A1 (es)
CO (1) CO2023000130A2 (es)
IL (1) IL299008A (es)
MX (1) MX2022015799A (es)
PE (1) PE20230837A1 (es)
WO (1) WO2021248207A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019001852A2 (pt) 2016-08-03 2019-05-07 Zelda Therapeutics Operations Pty Ltd composição de cannabis
KR20200104278A (ko) 2017-06-19 2020-09-03 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 수면 장애 조성물 및 그의 치료
US20220387256A1 (en) * 2021-06-03 2022-12-08 Kent Byron Vial With Metered Dispenser
US20250073252A1 (en) * 2021-08-03 2025-03-06 Pebble Global Holdings Non-psychoactive multi-cannabinoid and terpene-based therapeutic compositions and methods of their administration
EP4642238A1 (en) * 2023-12-28 2025-11-05 Linnea S.A. Process for stabilising a macerated oil

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3436001A1 (en) * 2016-03-28 2019-02-06 To Pharmaceuticals LLC Cannabionid and cannabis-based compositions and methods for the treatment of inflammatory conditions of the gastrointestinal tract
KR20190034576A (ko) * 2016-08-03 2019-04-02 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
US20180311180A1 (en) * 2016-12-29 2018-11-01 International Bioceutical Co. LLC Modular Transdermal Delivery Systems for the Treatment of Pain and Inflammation
WO2019036243A1 (en) * 2017-08-16 2019-02-21 Molecular Infusions, Llc Formulations
WO2019056128A1 (en) * 2017-09-25 2019-03-28 Canopy Health Innovations COMPOSITIONS COMPRISING CANNABIDIOL, TETRAHYDROCANNABINOL, TERPENES AND FLAVONOIDS AND THEIR USE IN THE TREATMENT OF INSOMNIA
US11857530B2 (en) * 2017-10-30 2024-01-02 Endocanna Health, Inc. Cannabinoid formulations
WO2019165387A1 (en) * 2018-02-23 2019-08-29 Spirtos Nicola Michael Cannabis based therapeutic and method of use
MX2020010603A (es) * 2018-04-09 2021-02-02 Ellevet Sciences Extracto de cáñamo para tratamiento de dolor en animales.
AU2018100928A4 (en) * 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Composition and method for opioid sparing
AU2018100924A4 (en) * 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Composition and method for treating pain
US20210392943A1 (en) * 2018-11-09 2021-12-23 Cronos Group Inc. Liquid composition for an electronic vapor device
CA3027876A1 (en) * 2018-12-18 2020-06-18 Tetra Bio-Pharma Cannabis compositions and methods

Also Published As

Publication number Publication date
CL2022003507A1 (es) 2023-06-09
KR20230069080A (ko) 2023-05-18
CN115843248A (zh) 2023-03-24
PE20230837A1 (es) 2023-05-19
WO2021248207A1 (en) 2021-12-16
AU2021215262B2 (en) 2023-12-14
IL299008A (en) 2023-02-01
EP4164628A4 (en) 2024-06-19
BR112022025302A2 (pt) 2023-02-28
CA3186718A1 (en) 2021-12-16
AU2021215262A1 (en) 2021-11-04
MX2022015799A (es) 2023-04-11
US20230218566A1 (en) 2023-07-13
EP4164628A1 (en) 2023-04-19
JP2023529476A (ja) 2023-07-10

Similar Documents

Publication Publication Date Title
CO2023000130A2 (es) Composición y método para el tratamiento del dolor crónico
CL2020003368A1 (es) Composicion y metodo para tratar el dolor
MX2021008702A (es) Uso de cannabinoides en el tratamiento de las comorbilidades asociadas a la epilepsia.
Farid et al. Oral intake of purple passion fruit peel extract reduces pain and stiffness and improves physical function in adult patients with knee osteoarthritis
MX2019015315A (es) Composiciones y tratamientos para el trastorno del sueño.
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
MX2021006094A (es) Uso de cannabinoides en el tratamiento de epilepsia.
CL2021002646A1 (es) Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicosactivos
MX2018011348A (es) Composiciones de extractos naturales y uso de los mismos para prevenir o tratar enfermedades.
MX383835B (es) Uso de cannabidiol en el tratamiento del complejo de escleroris tuberosa.
CL2024002956A1 (es) Conjugado anticuerpo-fármaco, método de preparación del mismo y uso del mismo.
MX2023006561A (es) Formulaciones farmaceuticas transdermicas que comprenden cbd o thc para el tratamiento del cancer.
BR112019001794A2 (pt) composição de cannabis
BR112021019262A2 (pt) Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose
AR122059A1 (es) Usos y formulaciones de cannabinoides
MX2021000023A (es) Composicion y metodo para el ahorro de opioides.
CL2021000882A1 (es) Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia.
NO20092763L (no) Isosorbid mononitrat derivater for behandling av tarmlidelser
CL2024002379A1 (es) Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso
BR112021019876A2 (pt) Inibidores de pde9 para tratar anemia falciforme
BRPI0913665B8 (pt) composição para tratamento de pressão intraocular aumentada em um paciente, compreendendo extratos de vaccinum myrtillus e de casca de pinheiro
BR112015023368A2 (pt) método de tratamento de deficiência de vitamina b12
MX2021008602A (es) Composicion para el tratamiento y/o prevencion de sintomas del tracto urinario inferior.
BR112022022204A2 (pt) Usos e formulações de canabinoides
PH12018000227B1 (en) A pharmaceutical composition for improving or preventing progression of chronic kidney disease